CESSATION OF THERAPY WITH ATENOLOL
Patients with coronary artery disease, who are being treated with atenolol, should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported in angina patients following the abrupt discontinuation of therapy with beta blockers. The last two complications may occur with or without preceding exacerbation of the angina pectoris. As with other beta blockers, when discontinuation of atenolol is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. If the angina worsens or acute coronary insufficiency develops, it is recommended that atenolol be promptly reinstituted, at least temporarily. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue atenolol therapy abruptly even in patients treated only for hypertension. (See DOSAGE AND ADMINISTRATION).
Atenolol Tablets, USP
Atenolol, a synthetic, beta1-selective (cardioselective) adrenoreceptor blocking agent, may be chemically described as Benzene-acetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-.
Atenolol tablets are indicated in the management of hypertension. They may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.
Angina Pectoris Due to Coronary Atherosclerosis
Atenolol tablets are indicated for the long-term management of patients with angina pectoris.
Acute Myocardial Infarction
Atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS.) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit.
Published Studies Related to Atenolol
Identifying iatrogenic depression using confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy. [2011.11.29]
BACKGROUND: beta-blockers and calcium channel blockers are highly effective medications indicated for treatment and prevention of hypertension. However, the literature regarding the potential depressive effects of beta-blockers and calcium channel blockers is equivocal regarding whether one or both are associated with depression. OBJECTIVES: To determine whether self-reported depressive symptoms of older persons with hypertension and coronary artery disease and who were randomly assigned to a verapamil-sustained-release-led (Ve-led) or atenolol-led (At-led) hypertension treatment strategy were similar using confirmatory factor analytical models of the Center for Epidemiologic Studies Depression Scale (CES-D)... CONCLUSIONS: The domains indicating less happiness and more depressive symptoms were most likely to be unfavorably impacted by the At-led treatment strategy. Given a choice between these equally effective high blood pressure treatment strategies, it may be prudent to use the Ve-led strategy. This is especially true if the risk of the occurrence of a mood-related side effect of the beta-blocker outweighs its other benefits in comparison. Copyright (c) 2011 Elsevier Inc. All rights reserved.
[Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. [2011.06]
INTRODUCTION AND OBJECTIVES: Marfan syndrome is an inherited disease of the connective tissue. Recent trials have indicated the use of losartan (a transforming growth factor beta inhibitor) in these patients prevents aortic root enlargement. The aim of our clinical trial is to assess the efficacy and safety of losartan versus atenolol in the prevention of progressive dilation of the aorta in patients with Marfan syndrome... CONCLUSIONS: Efficacy of losartan versus atenolol in the prevention of progressive dilation of the aorta, improved aortic distensibility, and prevention of adverse events (aortic dissection or rupture, cardiovascular surgery, or death) will be assessed in this study. It will also show the possible treatment benefits at different age ranges and with relation to the initial level of aortic root dilation. Copyright (c) 2011 Sociedad Espanola de Cardiologia. Published by Elsevier Espana. All rights reserved.
Comparison of the effects of ivabradine and atenolol on heart rate and echocardiographic variables of left heart function in healthy cats. [2011.05]
BACKGROUND: Ivabradine is a novel negative chronotropic drug used for treatment of ischemic heart disease in people. Little is known about its effects and safety in cats.Clinical studies in cats with hypertrophic cardiomyopathy are needed to validate these findings.
Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. [2011.01]
BACKGROUND: We evaluated the effect of atenolol vs metoprolol succinate on vascular function in patients with essential hypertension. HYPOTHESIS: Given intrinsic differences between these agents, we hypothesized that atenolol and metoprolol succinate would have disparate effects on vascular function... CONCLUSIONS: Although atenolol and metoprolol succinate have similar effects on blood-pressure reduction, they have different effects on vascular function. Compared with metoprolol succinate, atenolol increases peripheral AIx. Neither drug has an effect on vascular endothelial function. These findings may have clinical implications, depending on the indication for treatment in an individual patient. (c) 2011 Wiley Periodicals, Inc.
beta(1)-Adrenergic receptor gene polymorphisms and the acute response to atenolol in healthy young Japanese subjects. 
Polymorphisms at codons 49 and 389 of the beta(1)-adrenergic receptor gene have been shown to alter the receptor function in vitro, whereas it remains controversial whether they influence the response to beta-blocker in vivo. In the present study, we investigated whether these polymorphisms influence the acute changes of heart rate and blood pressure induced by the beta(1)-adrenergic receptor-selective blocker atenolol in healthy young Japanese...
Clinical Trials Related to Atenolol
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome [Recruiting]
Marfan syndrome is an inherited connective tissue disorder with morbidity and mortality from
aortic dilation and dissection. The degree of aortic dilation and response to beta-blockade
(standard of care) vary in adults with Marfan syndrome. However, aortic stiffness is often
present, and can be a predictor of aortic dilation and cardiovascular complications. In
addition, adults with Marfan syndrome develop left ventricular diastolic dysfunction, which
can progress to heart failure. Aortic stiffness and diastolic dysfunction are important and
logical therapeutic targets in adults with Marfan syndrome.
TGF-beta mediates disease pathogenesis in Marfan syndrome and contributes to aortic
stiffness. The angiotensin receptor blocker, losartan, inhibits TGF-beta activity and
reverses aortic wall pathology in a Marfan mouse model. Losartan also decreases aortic
stiffness and improves diastolic function in hypertension, renal disease and hypertrophic
This trial is a randomized, double-blind trial of 50 adults with Marfan syndrome, treated
with 6 months of atenolol vs. losartan. Arterial tonometry for aortic stiffness and
echocardiography for diastolic function will be performed at the beginning and end of
treatment. A blood draw for serum markers of extracellular matrix turnover and inflammation
will also be performed at 0 and 6 months. We plan to determine whether losartan decreases
aortic stiffness and left ventricular diastolic dysfunction significantly more than
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension [Recruiting]
This is a phase IV, prospective, multi-centric and randomized controlled study to compare
the effects of bisoprolol and atenolol on resting heart rate (RHR) and sympathetic nervous
system's (SNS) activity in subjects with essential hypertension. A total of 192 subjects are
planned to be enrolled in various centers in China.
Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques [Recruiting]
Nebivolol is a novel blood pressure lowering drug with an additional effect on the inner
lining of blood vessels to release a compound called nitric oxide that can relax blood
vessels. Atenolol is a blood pressure reducing agent without the ability to release nitric
oxide and effect additional blood vessel relaxation.
The goal of this proposal is to compare Nebivolol and Atenolol with respect to the following
- Plaque within arteries supplying the heart in terms of its volume and composition as
assessed by ultrasound within these arteries.
- Ability of small arteries in the heart to open up and deliver an enhanced blood supply
in response to drug called Adenosine (routinely used in the cardiac catheterization
laboratory) as assessed by pressure and flow detecting catheters within these arteries.
- Ability of the inner lining of arteries that supply the heart to release a relaxing
compound called nitric oxide in response to injection of Acetylcholine (also used in
the cardiac catheterization laboratory) as assessed by squirting dye into these
- Local forces that affect blood flow in the arteries supplying the heart as assessed by
superimposing the above data into complex maps created offline at Georgia Institute of
It is likely that Nebivolol causes the plaque within arteries supplying the heart to change
from the 'vulnerable' type to the 'stable' type plaque. There are several features of
"vulnerable plaques" that can be detected in arteries of the heart using intravascular
ultrasound (a small ultrasound camera that goes in the arteries of the heart). The
investigators hypothesis is that Nebivolol will prove superior to Atenolol in reducing
'vulnerable plaques', improve blood flow within the small arteries and the health of inner
lining of these arteries at the 1 year time point. The investigators plan to enroll 20
patients into the study (26 patient including dropouts) who will be randomized in a 1: 1
manner to Nebivolol Vs Atenolol for 1 year and repeat evaluation at that time point.
A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function [Recruiting]
This is a randomized, double-blind, placebo-controlled study comparing the efficacy of
nebivolol and atenolol at improving small artery elasticity and reducing cardiovacular
disease risk in subjects with early vascular disease. Approximately 75 subjects with
borderline/elevated blood pressures and impaired endothelial function, as measured by
arterial elasticity scores, will be recruited and assigned to treatment groups using a block
randomization scheme. Patients will be randomly allocated to nebivolol, atenolol or
placebo, and then followed for 9 months.
Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure [Recruiting]
The purpose of this research study is to determine whether atenolol or controlled release
carvedilol lower blood pressure in the body as effectively as in the arm. Blood pressure
measured in the aorta, a large blood vessel carrying blood away from the heart, may be a
better measure of the harmful effects of high blood pressure on the body's organs. In the
past, blood pressure has only been measured in the arms. However, blood pressure in the
arms may not accurately reflect the blood pressure in the aorta and thus may mislead doctors
treating high blood pressure. For this reason, we are testing whether two different
medications for blood pressure, both in a class called beta blockers, have similar effects
on blood pressure in the arm and aorta.
Reports of Suspected Atenolol Side Effects
Completed Suicide (151),
Toxicity TO Various Agents (65),
Blood Pressure Increased (62),
Drug Ineffective (51),
Cardiac Arrest (46),
Renal Failure Acute (44),
Dizziness (42), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 12 ratings/reviews, Atenolol has an overall score of 8. The effectiveness score is 8 and the side effect score is 7.83. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Atenolol review by 60 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || Extra Heartbeat|
|Dosage & duration:|| || 25 mg/day taken 1 /day for the period of 13+ years|
|Other conditions:|| || None|
|Other drugs taken:|| || None|
|Benefits:|| || The benefits are amazing. I felt dizzy and like I was going to faint before I took the drug. These symptoms went away and have stayed away for going on 20 years. I also have seen that it helps with blood pressure and pulse rate. |
|Side effects:|| || I have never experienced any adverse side affects.|
|Comments:|| || I simply take one tiny tablet each morning.|
Atenolol review by 67 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Moderately Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || hypertension|
|Dosage & duration:|| || 25 mg taken 1 po qd for the period of 3 years|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || Effective in reducing hypertension from previous approximately 170/85 to less than 150/65 and now even less at approximately 130/65|
|Side effects:|| || Side effected included sleepiness, and unaccountably nausea while sailing. Prior to taking this drug I had never had problems with "seasickness" while sailing. I found I had to stay topside during sailing times. Other than that, the tiredness was a factor which became less noticeable with time. The seasickness would not be a problem for the majority of people, I am sure|
|Comments:|| || Treatment was 1 pill per day for approximately 3 years (25 mg) which I am told is a quite low dose for this medication. However my weight is 100 lbs on average and small build so for me it was more than enough. It helped my hypertension come back to within normal range which I was pleased with. If I needed to go back on an antihypertensive, I would try it again |
Atenolol review by 62 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || Severe Side Effects|
|Condition / reason:|| || Atrial Fibrillation|
|Dosage & duration:|| || 25 mg taken daily for the period of 3 months|
|Other conditions:|| || mild hypertension|
|Other drugs taken:|| || warafin, lisinopril|
|Benefits:|| || none except....slowed heart rate. My afib was NOT diminished, but I assume the drug was helping keep my heart rate when in Afib down somewhat|
|Side effects:|| || The 3 months i was on atenolol (25mg) I had vertigo, short term memory loss, anxiety, and hearing issue. All except hearing went away when I switched to a different beta blocker.
|Comments:|| || once a day 25 mg|
Page last updated: 2011-12-09